As global microbial fermentation technology enters the era of “precision transformation,” GeneFerm Biotechnology, a leading fermentation expert from Taiwan, is set to launch its global strategic expansion in the summer of 2026.

The first stop will be Vitafoods Europe 2026 in Spain this May, followed by a return to Taipei for BIO Asia–Taiwan 2026. With a large-scale fermentation capacity of up to 400 metric tons, GeneFerm aims to empower global partners in developing scientifically validated and competitive products.

Core Technology Showcase: Demonstrating True Expertise in Fermentation

At this year’s exhibitions, GeneFerm will highlight how its advanced fermentation technologies are translated into high-performance ingredient solutions. The company specializes in Precision Fermentation and Anaerobic Fermentation, with clients spanning Europe, the United States, Japan, and the Middle East.

Key highlights include:

1. 【GFRena2 Probiotics】 A Benchmark in Scientific Excellence
   Backed by rigorous clinical data, GFRena2 has received the 19th National Innovation Award and holds both Taiwan and U.S. patents, making it one of the few probiotic solutions combining scientific validation with targeted functionality.
2. 【AquaSoiivon® Fermented Soy Extract】 A Premium Solution for Healthy Aging
   Utilizing the patented ActiConvert™ fermentation technology, this ingredient significantly enhances bioavailability. It has been awarded a gold medal at the IIIC International Innovation & Invention Competition and is gaining strong market attention as an advanced solution for healthy aging.
3. 【One-Stop Dosage Form Development】 Accelerating Time-to-Market
   GeneFerm provides comprehensive solutions from raw materials to finished formats such as functional jellies and liquid supplements, helping brands rapidly commercialize scientific innovations into market-ready products.

Expanding into Europe: Showcasing 66-Ton Fermentation Capability at Vitafoods Europe

To meet the European market’s high standards for premium ingredients and stable supply, GeneFerm will exhibit in Barcelona from May 5 to May 7, 2026.
A key competitive advantage lies in its 66-ton large-scale fermentation tanks, enabling seamless integration from laboratory development to full-scale commercial production through one-stop CDMO services—an essential factor in attracting leading European brands.

Leading Preventive Healthcare in Asia: Integration Strength at BIO Asia–Taiwan

From July 16 to July 19, 2026, GeneFerm will return to Taipei to showcase its ODM/OEM services tailored for the Asian market.
Its core strength lies in rapidly transforming laboratory innovations into commercially viable products. GeneFerm’s CDMO services have earned strong recognition from both domestic and international partners, reflecting its leadership in quality consistency and cost control.

Driving Value in the Global Health Industry

From Barcelona to Taipei, GeneFerm continues to optimize its global supply chain through strategic action. Moving forward, the company will further invest in microbial technology innovation, partnering with global clients to create new milestones in the evolving health and biotechnology industry.